{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:41:16Z","timestamp":1782942076947,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,23]],"date-time":"2013-09-23T00:00:00Z","timestamp":1379894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,9,23]],"date-time":"2013-09-23T00:00:00Z","timestamp":1379894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1038\/bmt.2013.133","type":"journal-article","created":{"date-parts":[[2013,9,23]],"date-time":"2013-09-23T10:40:39Z","timestamp":1379932839000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study"],"prefix":"10.1038","volume":"49","author":[{"given":"L G","family":"Lum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Kouttab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Deol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W M","family":"Colaiace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,23]]},"reference":[{"key":"BFbmt2013133_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1042\/bst0250705","volume":"25","author":"DR Anderson","year":"1997","unstructured":"Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N . Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997; 25: 705\u2013708.","journal-title":"Biochem Soc Trans"},{"key":"BFbmt2013133_CR2","first-page":"149","volume-title":"Stem Cell and Targeted Therapy Proceedings of the 11th INt'l Symposium","author":"JF Lambert","year":"2003","unstructured":"Lambert JF, Rahore R, Lum LG, Oblon DJ, Malik SP, Colvin GA et al. Immune consolidation with rituximab following autologous stem cell transplantation for non-Hodgkin's lymphoma: An interim report of a pilot study with historical controls. In: Dicke KA, Keating A (eds). Stem Cell and Targeted Therapy Proceedings of the 11th INt'l Symposium. Carden Jennings: Charlottesville, NC, 2003 pp 149\u2013161."},{"key":"BFbmt2013133_CR3","first-page":"295b","volume":"102","author":"GJ Elfenbein","year":"2003","unstructured":"Elfenbein GJ, Lum LG, Rathore R, Lambert JF, Falvey MT . Interim report of an historically controlled trial of rituximab after autologous stem cell transplanation for non-Hodgkin's lymphoma. Blood 2003; 102: 295b.","journal-title":"Blood"},{"key":"BFbmt2013133_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","volume":"103","author":"SM Horwitz","year":"2004","unstructured":"Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin\u2019s lymphoma. Blood 2004; 103: 777\u2013783.","journal-title":"Blood"},{"key":"BFbmt2013133_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/sj.bmt.1705649","volume":"39","author":"K Kamezaki","year":"2007","unstructured":"Kamezaki K, Kikushige Y, Numata A, Miyamoto T, Takase K, Henzan H et al. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. Bone Marrow Transplant 2007; 39: 523\u2013527.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013133_CR6","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188\u20132195.","journal-title":"Blood"},{"key":"BFbmt2013133_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/sonc.2003.50025","volume":"30","author":"P Johnson","year":"2003","unstructured":"Johnson P, Glennie M . The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003; 30: 3\u20138.","journal-title":"Semin Oncol"},{"key":"BFbmt2013133_CR8","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","volume":"101","author":"O Manches","year":"2003","unstructured":"Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949\u2013954.","journal-title":"Blood"},{"key":"BFbmt2013133_CR9","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR . Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359\u20137368.","journal-title":"Oncogene"},{"key":"BFbmt2013133_CR10","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","volume":"171","author":"N Di Gaetano","year":"2003","unstructured":"Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581\u20131587.","journal-title":"J Immunol"},{"key":"BFbmt2013133_CR11","unstructured":"Lum LG . Immunotherapy with activated T cells after high dose chemotherapy and PBSCT for breast cancer. In: Dicke KA, Keating A (eds). Carden Jennings: Charlottesville, NY, 2000 pp 95\u2013105."},{"key":"BFbmt2013133_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.exphem.2005.01.007","volume":"33","author":"JM Gall","year":"2005","unstructured":"Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG . T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B-cells and bypass complement-mediated Rituximab-resistance in vitro. Exp Hematol 2005; 33: 452\u2013459.","journal-title":"Exp Hematol"},{"key":"BFbmt2013133_CR13","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.4049\/jimmunol.124.6.2708","volume":"124","author":"JP Van Wauwe","year":"1980","unstructured":"Van Wauwe JP, De Mey JR, Gooseens JG . OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 1980; 124: 2708\u20132713.","journal-title":"J Immunol"},{"key":"BFbmt2013133_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(08)60029-2","volume":"41","author":"A Weiss","year":"1987","unstructured":"Weiss A, Imboden JB . Cell surface molecules and early events involved in human T lymphocyte activation. Adv Immunol 1987; 41: 1\u201338.","journal-title":"Adv Immunol"},{"key":"BFbmt2013133_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/BF00205763","volume":"27","author":"PM Anderson","year":"1988","unstructured":"Anderson PM, Bach FH, Ochoa AC . Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma. Cancer Immunol Immunother 1988; 27: 82\u201388.","journal-title":"Cancer Immunol Immunother"},{"key":"BFbmt2013133_CR16","first-page":"963","volume":"49","author":"AC Ochoa","year":"1989","unstructured":"Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH . Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets. Cancer Res 1989; 49: 963\u2013968.","journal-title":"Cancer Res"},{"key":"BFbmt2013133_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/15258160151134944","volume":"10","author":"M Sen","year":"2001","unstructured":"Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV et al. Use of anti-CD3 x anti-HER2\/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2\/neu tumors. J Hematother Stem Cell Res 2001; 10: 247\u2013260.","journal-title":"J Hematother Stem Cell Res"},{"key":"BFbmt2013133_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1006\/clin.1994.1034","volume":"70","author":"JP Uberti","year":"1994","unstructured":"Uberti JP, Joshi I, Ueda M, Martilotti F, Sensenbrenner LL, Lum LG . Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non-MHC restricted cytotoxicity. Clin Immunol Immunopathol 1994; 70: 234\u2013240.","journal-title":"Clin Immunol Immunopathol"},{"key":"BFbmt2013133_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00007890-199308000-00019","volume":"56","author":"M Ueda","year":"1993","unstructured":"Ueda M, Joshi ID, Dan M, Uberti JP, Chou T-H, Sensenbrenner LL et al. Preclinical studies for adoptive immunotherapy in bone marrow transplantation: II. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates. Transplantation 1993; 56: 351\u2013356.","journal-title":"Transplantation"},{"key":"BFbmt2013133_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1158\/1078-0432.CCR-05-2005","volume":"12","author":"RC Grabert","year":"2006","unstructured":"Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB et al. Human T cells armed with Her2\/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 2006; 12: 569\u2013576.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2013133_CR21","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den NE, Lepeu G, Plantier I, Castaigne S et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040\u20132045.","journal-title":"Blood"},{"key":"BFbmt2013133_CR22","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1200\/JCO.1992.10.10.1615","volume":"10","author":"A Bosly","year":"1992","unstructured":"Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, Andrien F et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992; 10: 1615\u20131623.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013133_CR23","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der LH, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540\u20131545.","journal-title":"N Engl J Med"},{"key":"BFbmt2013133_CR24","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2005.08.012","volume":"23","author":"IF Khouri","year":"2005","unstructured":"Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin\u2019s lymphomas. J Clin Oncol 2005; 23: 2240\u20132247.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013133_CR25","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/bmt.2011.218","volume":"47","author":"T Ahmadi","year":"2011","unstructured":"Ahmadi T, McQuade J, Porter D, Frey N, Loren AW, Goldstein SC et al. Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Bone Marrow Transplant 2011; 47: 1082\u20131086.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013133_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.7150\/jca.2.331","volume":"2","author":"DL Porter","year":"2011","unstructured":"Porter DL, Kalos M, Zheng Z, Levine B, June C . Chimeric antigen receptor therapy for B-cell malignancies. J Cancer 2011; 2: 331\u2013332.","journal-title":"J Cancer"},{"key":"BFbmt2013133_CR27","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.","journal-title":"Sci Transl Med"},{"key":"BFbmt2013133_CR28","first-page":"1","volume-title":"Phase I Clinical Trial Involving Infusions of Activated T Cells Armed with Anti-CD3 x Anti-Her2neu Bispecific Antibody in Women with Metastatic Breast Cancer: Clinical, Immune, and Trafficking Results.Oct","author":"LG Lum","year":"2010","unstructured":"Lum LG, Thakur A, Rathore R, Al-Kadhimi Z, Uberti JP, Rathanatharathorn V . Phase I Clinical Trial Involving Infusions of Activated T Cells Armed with Anti-CD3 x Anti-Her2neu Bispecific Antibody in Women with Metastatic Breast Cancer: Clinical, Immune, and Trafficking Results.Oct. ASCO Breast Cancer Symposium 2010: Washington, DC, 1\u20133 2010."},{"key":"BFbmt2013133_CR29","first-page":"340","volume":"12","author":"A Thakur","year":"2010","unstructured":"Thakur A, Lum LG . Cancer therapy with bispecific antibodies: clinical experience. Curr Opin Mol Ther 2010; 12: 340\u2013349.","journal-title":"Curr Opin Mol Ther"},{"key":"BFbmt2013133_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-3-642-20910-9_14","volume-title":"Bispecific Antibodies","author":"LG Lum","year":"2011","unstructured":"Lum LG, Thakur A . Bispecific antibodies for arming activated T cells and other effector cells for tumor therapy. In: Kontermann RE (eds). Bispecific Antibodies. Springer-Verlag Berlin Heidelberg: Stuttgart, pp 243\u2013271 2011."},{"key":"BFbmt2013133_CR31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.bbmt.2013.03.010","volume":"19","author":"LG Lum","year":"2013","unstructured":"Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L et al. CD20-Targeted T Cells after Stem Cell Transplantation for Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant 2013; 19: 925\u2013933.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013133_CR32","first-page":"1331","volume":"23","author":"N-R Jin","year":"1995","unstructured":"Jin N-R, Lum LG, Ratanatharathorn V, Sensenbrenner LL . Anti-CD3-activated splenocytes enhance survial in lethally irradiated mice after transplant of syngeneic hematopoietic stem cells. Exp Hematol 1995; 23: 1331.","journal-title":"Exp Hematol"},{"key":"BFbmt2013133_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.bbmt.2007.06.010","volume":"13","author":"EO Hexner","year":"2007","unstructured":"Hexner EO, net-Desnoyers GA, Zhang Y, Frank DM, Riley JL, Levine BL et al. Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. Biol Blood Marrow Transplant 2007; 13: 1135\u20131144.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013133_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.bbmt.2013.03.010","volume":"9","author":"LG Lum","year":"2013","unstructured":"Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L et al. CD20-targeted T cells after stem cell transplant for high risk and refractory non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2013; 9: 925\u2013933.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2013133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013133","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2013133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T19:19:57Z","timestamp":1688498397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2013133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,23]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["BFbmt2013133"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.133","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,23]]},"assertion":[{"value":"29 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Lum is co-founder of Transtarget, Inc. The other authors declare no conflict of interest","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}